Journal: Journal of Cellular and Molecular Medicine
Article Title: LncRNA‐ATB regulates epithelial‐mesenchymal transition progression in pulmonary fibrosis via sponging miR‐29b‐2‐5p and miR‐34c‐3p
doi: 10.1111/jcmm.16758
Figure Lengend Snippet: TGF‐β1 promotes EMT process and decreases miR‐29b‐2‐5p and miR‐34c‐3p levels. A, Western blot analysis of E‐cadherin, Vimentin, Fibronectin and α‐SMA in A549 cells and BEAS‐2B cells treated with 0, 1, 2 and 5 ng/mL TGF‐β1 for 48 h. B, Western blot analysis of E‐cadherin, Vimentin, Fibronectin and α‐SMA in human primary type II AECs treated with 0 or 5 ng/mL TGF‐β1 for 48 h. C, Wound healing assays were performed to measure the migration ability of A549 cells treated with 0, 1, 2 and 5 ng/mL TGF‐β1 for 48 h. D, Immunofluorescence staining of Vimentin and E‐cadherin in A549 cells for the control and TGF‐β1 (0 or 5 ng/mL) treatment groups. Green represents Vimentin staining; red represents E‐cadherin staining; and blue represents nuclear DNA staining by DAPI. The scale bar is 50 μm. E, qRT‐PCR detection of lncRNA‐ATB expression in 0, 1, 2 and 5 ng/mL TGF‐β1 treated A549 and BEAS‐2B cells for 48 h (mean ± SD, n = 3), * P < .05 difference from untreated cells. F, qRT‐PCR analysis of miR‐29b‐2‐5p and miR‐34c‐3p expression in 0, 1, 2 and 5 ng/mL TGF‐β1 treated A549 and BEAS‐2B cells for 48 h (mean ± SD, n = 3), * P < .05 difference from untreated cells. G, qRT‐PCR detection of lncRNA‐ATB, miR‐29b‐2‐5p and miR‐34c‐3p expression in human primary type II AECs after 0 or 5 ng/mL TGF‐β1 treatment (mean ± SD, n = 3), * P < .05
Article Snippet: Human primary type II alveolar epithelial cells (AECs) were obtained from Procell Biotechnology and cultured in human type II alveolar epithelial cell medium.
Techniques: Western Blot, Migration, Immunofluorescence, Staining, Control, Quantitative RT-PCR, Expressing